MMEA
LEGN icon

Main Management ETF Advisors’s Legend Biotech LEGN Stock Holding History

Main Management ETF Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,622
Closed -$579K – 157
2025
Q4 		$579K Buy
26,622
+272
+1% +$7.79K 0.02% 122
2025
Q3 		$859K Buy
+26,350
New +$973K 0.03% 113

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Main Management ETF Advisors's LEGN Position: Q1 2026 in Review

Main Management ETF Advisors sold out of Legend Biotech (LEGN) in Q1 2026, closing a stake of 26,622 shares — an estimated $579K sold.

Main Management ETF Advisors first reported a position in LEGN in Q3 2025 and held it in 2 quarters. The position peaked at $859K in Q3 2025. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Main Management ETF Advisors reported no remaining Legend Biotech position as of Q1 2026 after selling out during the quarter.
  • Main Management ETF Advisors sold 26,622 Legend Biotech shares in Q1 2026, an estimated $579K.
  • Main Management ETF Advisors first reported a position in Legend Biotech in Q3 2025 and held it in 2 quarters.
  • Main Management ETF Advisors's Legend Biotech position peaked at $859K in Q3 2025.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Main Management ETF Advisors's 13F filing for Q1 2026, filed 15 May 2026.